Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences

PASADENA, Calif.–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;$arwrlt;/agt;–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is
scheduled to present at the following upcoming events:

Barclays Global Healthcare Conference 2019 – Miami, March 12-14,

March 12, 4:20 p.m. EDT – Bruce Given, M.D., Arrowhead’s chief
operating officer, will deliver a corporate presentation

Jefferies HBV Investor Summit – New York, March 18, 2019

March 18, 9:30 a.m. EDT – Dr. Given will participate in a
fireside chat presentation with Maury Raycroft, Ph.D., Jefferies Biotech

Oligonucleotide & Precision Therapeutics (OPT) Congress
Cambridge, MA, March 26-27, 2019

March 26, 4:35 p.m. EDT – James Hamilton, M.D., Arrowhead’s vice
president of clinical development, will deliver an oral presentation
titled, “siRNA Clinical Development Based on the TRiM™ Platform”

CSHL Meeting: RNA & Oligonucleotide Therapeutics – Cold
Spring Harbor, NY, March 27-30, 2019

Dr. Hamilton will deliver an oral presentation titled, “Cardiovascular
and lipid disorders – A next frontier for TRiM™ RNAi”

AACR Annual Meeting 2019 – Atlanta, March 29 – April 3, 2019

April 3, 8:00 a.m. EDT – So Wong, Ph.D., Arrowhead’s director of
oncology, will deliver a poster presentation titled, “Optimizing the
potency and dosing design for ARO-HIF2: An RNAi therapeutic for clear
cell renal cell carcinoma”

A copy of the presentation materials and webcast links, if the
presentation is being webcast, may be accessed on the Events
and Presentations
page under the Investors section of the Arrowhead

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.

For more information, please visit,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit

Safe Harbor Statement under the Private Securities Litigation Reform

This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the likelihood and
timing of the receipt of future milestone and licensing fees, the future
success of our scientific studies, our ability to successfully develop
and commercialize drug candidates, the timing for starting and
completing clinical trials, rapid technological change in our markets,
and the enforcement of our intellectual property rights. Our most recent
Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q
discuss some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no obligation
to update or revise forward-looking statements to reflect new events or

Source: Arrowhead Pharmaceuticals, Inc.


Arrowhead Pharmaceuticals, Inc.
Anzalone, CFA

Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie

error: Content is protected !!